These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 26106454)

  • 21. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
    Paterson NE; Min W; Hackett A; Lowe D; Hanania T; Caldarone B; Ghavami A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1455-64. PubMed ID: 20708056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Psychopharmacology Update: Additional Safety Concerns for Using Varenicline (Chantix) for Smoking Cessation Treatment.
    Tobin TJ; Tobin ML
    Issues Ment Health Nurs; 2015; 36(10):840-3. PubMed ID: 26514264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smoking cessation with varenicline: a suicidal fatality.
    Kintz P; Evans J; Villain M; Cirimele V
    J Anal Toxicol; 2009 Mar; 33(2):118-20. PubMed ID: 19239738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
    Tonstad S; Davies S; Flammer M; Russ C; Hughes J
    Drug Saf; 2010 Apr; 33(4):289-301. PubMed ID: 20297861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
    Raybuck JD; Portugal GS; Lerman C; Gould TJ
    Behav Neurosci; 2008 Oct; 122(5):1166-71. PubMed ID: 18823172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study.
    Boudrez H; Gratziou C; Messig M; Metcalfe M
    Curr Med Res Opin; 2011 Apr; 27(4):769-75. PubMed ID: 21294601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing the dose of varenicline in patients who do not respond to the standard dose.
    Jiménez-Ruiz CA; Barrios M; Peña S; Cicero A; Mayayo M; Cristóbal M; Perera L
    Mayo Clin Proc; 2013 Dec; 88(12):1443-5. PubMed ID: 24290118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective poison center review of varenicline-exposed patients.
    Kreshak AA; Clark AK; Clark RF; Ly BT; Cantrell FL
    Ann Pharmacother; 2009 Dec; 43(12):1986-91. PubMed ID: 19934384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Varenicline, the clinically effective smoking cessation agent, restores probabilistic response reversal performance during withdrawal from nicotine.
    Jackson A; Silk S; Buhidma Y; Shoaib M
    Addict Biol; 2017 Sep; 22(5):1316-1328. PubMed ID: 27440124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
    Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
    J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Varenicline provokes impulsive action by stimulating α4β2 nicotinic acetylcholine receptors in the infralimbic cortex in a nicotine exposure status-dependent manner.
    Ohmura Y; Sasamori H; Tsutsui-Kimura I; Izumi T; Yoshida T; Yoshioka M
    Pharmacol Biochem Behav; 2017 Mar; 154():1-10. PubMed ID: 28087221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Varenicline: an aid to smoking cessation therapy].
    Perez-Bogerd S; Sternon J
    Rev Med Brux; 2007; 28(6):523-6. PubMed ID: 18265811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of nicotine dependence with Chantix (varenicline).
    Rankin KV; Jones DL
    Tex Dent J; 2011 May; 128(5):457-61. PubMed ID: 21834368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Varenicline--a new chance for smokers?].
    Goniewicz ML; Koszowski B; Czogała J; Sobczak A
    Przegl Lek; 2007; 64(10):899-902. PubMed ID: 18409337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.
    Goutier W; Kloeze MB; McCreary AC
    Addict Biol; 2015 Mar; 20(2):248-58. PubMed ID: 24251901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.